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Abstract: Schistosoma mansoni is a parasite which causes significant public-health issues, with over
240 million people infected globally. In Uganda alone, approximately 11.6 million people are af-
fected. Despite over a decade of mass drug administration in this country, hyper-endemic hotspots
persist, and individuals who are repeatedly heavily and rapidly reinfected are observed. Human
blood-type antigens are known to play a role in the risk of infection for a variety of diseases, due
to cross-reactivity between host antibodies and pathogenic antigens. There have been conflicting
results on the effect of blood type on schistosomiasis infection and pathology. Moreover, the effect
of blood type as a potential intrinsic host factor on S. mansoni prevalence, intensity, clearance, and
reinfection dynamics and on co-infection risk remains unknown. Therefore, the epidemiological link
between host blood type and S. mansoni infection dynamics was assessed in three hyper-endemic
communities in Uganda. Longitudinal data incorporating repeated pretreatment S. mansoni in-
fection intensities and clearance rates were used to analyse associations between blood groups in
school-aged children. Soil-transmitted helminth coinfection status and biometric parameters were
incorporated in a generalised linear mixed regression model including age, gender, and body mass
index (BMI), which have previously been established as significant factors influencing the prevalence
and intensity of schistosomiasis. The analysis revealed no associations between blood type and
S. mansoni prevalence, infection intensity, clearance, reinfection, or coinfection. Variations in infection
profiles were significantly different between the villages, and egg burden significantly decreased
with age. While blood type has proven to be a predictor of several diseases, the data collected in
this study indicate that it does not play a significant role in S. mansoni infection burdens in these
high-endemicity communities.
Keywords: schistosomiasis; blood group; susceptibility; rhesus; coinfection; STH
1. Introduction
Schistosomiasis is a debilitating, neglected tropical disease with over 240 million
people infected globally [1]. Despite over a decade of mass drug administration (MDA) in
many sub-Saharan African countries, hyperendemic hotspots persist, where individuals are
repeatedly heavily and rapidly reinfected [2,3]. A range of factors may contribute to persis-
tent hotspots relating to the environment, such as sanitation or snail habitat suitability [4,5];
and to parasite or host influences, including variation in genetic background, immune
responses [6], and/or drug efficacy [7]. Individuals can vary in their predisposition to
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helminth infections [8], and, in particular, blood group has been hypothesised to contribute
to schistosome susceptibility [9].
Associations between blood type and disease susceptibility or severity have been
described [10]. A and/or B antigens are thought to be advantageous in conferring resistance
to some pathogens [11]. For example, the prevalence of Ancylostoma duodenale (Hookworm)
was found to be higher in individuals with an O blood type than in those with A or B
antigens [12]. However, in some instances, A and/or B antigens increase susceptibility
to some diseases. For example, non-O groups have been associated with increased risk
and severity of acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection [13].
Individuals with blood group O appear to have a lower susceptibility to the virus [14],
and group A shows a higher susceptibility to infection [15]. Susceptibility to both malaria
and tuberculosis is highest in individuals with blood group B, due to the structurally
similar α-Gal surface proteins on blood-cell and pathogen surfaces [16]. Variance in
disease susceptibility amongst the blood types is thought to be mediated by cross-reacting
responses, where anti-A or anti-B antibodies detect foreign proteins expressing A and B
motifs or conversely do not detect them if they do not possess these antibodies [10,17].
Pathogens expressing A- and/or B-type epitope sequences are more likely to be detected
by the host immune system of individuals with an O-type blood group [18]. Geographical
variation among blood-type groups illustrates that pathogen selection can influence co-
evolution between blood-group antigens and pathogens [19].
There are few studies solely investigating the impact of Rhesus (Rh) blood groups
on disease. Variation in surface proteins on blood cells in Rh-negative individuals have
been found to facilitate viral binding in West Nile Virus and thereby increase susceptibility
of contracting West Nile Virus [20]. A recent study has found a correlation between
Rh positivity and a predisposition to SARS-CoV-2 [21]. The risk of contracting dengue
haemorrhagic fever is increased in Rh-positive individuals [22]. These studies suggest
that there is a correlation between Rh blood types and infectious disease, but the effect
is disease-specific.
One mechanism parasites use to evade immune defence is through the adhesion to
host proteins. Several studies have reported a relationship between antigen acquisition
and evasion of host immune responses [9]. Early work in this area has described the
occurrence of adsorption of host antigens containing glycoproteins and glycolipids by
schistosomes. This is also thought to include blood groups [23–25]. Adhesion of host
proteins is understood to occur within the membranocalyx or inter-membrane zones
of the schistosome tegument, wherein studies have detected internalised host-derived
immunological proteins [26,27]. Further, structural similarities occur between human-blood
proteins in A blood groups (GalNAc) and schistosome polysaccharides [28,29], potentially
leading to increased susceptibility to schistosome infections and greater infection intensities.
Meanwhile, individuals with B or O blood types may be more efficient at eliciting an anti-A
immune response [29]. Therefore, the occurrence of blood-group protein adhesion by
schistosomes may contribute to the magnitude of immunological detection by the host and
might explain variation in prevalence, intensity, and severity among endemic populations.
Of the few studies that have attempted to establish a relationship between blood
group and prevalence, intensity or severity of S. mansoni infections, the results have been
conflicting [9]. A recent study found that individuals with an AB blood type are four
times more likely to have a high egg burden than those with an O group [30]. This study
focused on infection intensity based on one stool sample and did not look at the impact of
blood group on clearance after treatment. Several studies have found that patients with A
blood groups display an increased schistosomiasis disease severity, and O groups exhibit
the lowest prevalence and intensity of schistosomes [31–33]. These studies also focused
on infection status at the time of sampling and did not consider the longitudinal impact
of blood type on schistosome infection dynamics over time or with drug treatment, and
subsequent clearance, and reinfection. One study that did look at longitudinal data assessed
the annual incidence of schistosome infection and found that individuals with A-type blood
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had the highest intensities and annual incidence of both S. mansoni and S. haematobium [34].
Conversely, another study found that the group with most prevalent S. mansoni infections
at a single time point was type B [35]. Earlier work conducted by Katz et al. found no
significant difference between blood groups and S. mansoni prevalence amonst patients
with hepatosplenic schistosomiasis [36]. A study by Kassim and Eiezie (1982) examined
the rate of Schistosoma haematobium and malaria infection and found that the frequencies of
blood groups were not associated with infection rates [37]. However, diagnostic methods
and sensitivities, and host–pathogen interactions, including the potential effect of host
blood type, differ between S. mansoni and S. haematobium [38]. The above discrepancies
indicate a need to expand knowledge on the interaction between blood type and S. mansoni
infection dynamics in an endemic setting [9]. There are currently no published studies
looking at the role blood type plays on treatment efficacy in schistosome infections or any
longitudinal studies to determine whether blood type is a risk factor for repeated or rapid
re/infection. Furthermore, no studies have investigated the effect host blood group may
have on coinfection with soil-transmitted helminths (STHs) and schistosomes, despite how
they commonly co-occur and are often co-treated at the same time through many national
control programmes.
The purpose of this study was to evaluate the association between host blood type
and its effect on S. mansoni infection dynamics, with repeated observations over time in
school-aged children (SAC). Specifically, the aim was to analyse repeat monitoring data
about infection/coinfection predisposition, prevalence, intensity, clearance, and reinfection
post-treatment, so that a comprehensive representation could be assessed in relation to the
impact that blood group may have on these parameters in areas where these S. mansoni
dynamics remain high despite over 15 years of MDA.
2. Materials and Methods
A total of 630 school children between the ages of 6 and 14 were recruited from three
primary schools in Mayuge district Uganda, all in high S. mansoni endemicity villages along
the shores of Lake Victoria. An equal ratio of boys and girls were recruited and evenly
distributed between year age groups. Two hundred and seventy children were recruited
from Bugoto Lake View Primary School (0◦ 1924.09′′ N, 33◦3741.40′′ E) in September
2017. One hundred and eighty children were recruited from both Bwondha Primary
School (0◦117.15′′ N, 33◦3339.87′′ E) and Musubi Church of Uganda God Primary School
(0◦1849.45′′ N, 33◦3947.50′′ E) in September 2017 and October 2017, respectively.
In each school, three days of duplicate Kato–Katz thick smears were prepared, in ac-
cordance with established protocol [39], from three stool samples provided by participants.
On the third day, after sample collection, the participants were all given a meal of porridge
and butter an hour prior to observed treatments with 40 mg/kg of praziquantel and 400 mg
of albendazole. Individuals from the three schools were all followed up approximately
six months later to quantify reinfection rates; they were then retreated with 40 mg/kg
praziquantel and followed up with three weeks later to quantify clearance post-treatment.
Sample and treatment dates are shown in Figure 1.
In September 2019, participants provided a finger-prick blood sample to identify blood
type. A small drop of blood was spotted onto glass slides and mixed with anti-A, anti-B
monoclonal sera and an anti-D blend (Alpha Laboratories, Ltd., Hampshire, UK). The
slides were checked for agglutination by trained technicians within 10 min of mixing blood
and antisera.
Criteria for inclusion in the blood group study included parental consent, child assent,
and the provision of a finger-prick blood sample and a stool sample at one or more time
point/s.
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Figure 1. Kato–Katz thick smear sampling (three days of duplicate Kato–Katz at each time point) 
and praziquantel treatment timeline, indicating the weeks sampling occurred in each school. Trian-
gles indicate praziquantel administration given, after stool samples were collected, on that week, 
and circles denote treatment was only administered to children with Schistosoma mansoni detected 
infections. 
In September 2019, participants provided a finger-prick blood sample to identify 
blood type. A small drop of blood was spotted onto glass slides and mixed with anti-A, 
anti-B monoclonal sera and an anti-D blend (Alpha Laboratories, Ltd., Hampshire, UK). 
The slides were checked for agglutination by trained technicians within 10 min of mixing 
blood and antisera. 
Criteria for inclusion in the blood group study included parental consent, child as-
sent, and the provision of a finger-prick blood sample and a stool sample at one or more 
time point/s. 
Because the schools were not all sampled on the same dates, the number of weeks at 
follow-up was controlled for in the analysis. Participants were excluded from the study if 
weight and height information collected at baseline or blood-group data were missing. 
Loss to follow-up was high; therefore, only 265 individuals were included in the final 
analysis. 
To assess the role that blood type plays in predisposition to infection and to deter-
mine its effect on clearance, prevalence, and intensity, a generalised linear mixed-effects 
model was performed, using the glmmTMB [40] package in R ver. 3.5.1 [41]. Negative 
binomial model assumptions were assessed by using several error structures, including 
both nbinom1 and nbinom2 parameters, as well as Poisson distributions [40]. The 
nbinom2 error distribution had minimal residual variance compared with the other error 
structures assessed and was therefore chosen as the best fit for the data. Residuals were 
assessed for uniformity, using the DHARMa package [42]. Briefly, a bootstrapped simu-
lation of residuals was performed, along with Kolmogorov–Smirnov uniformity tests; 
quantile regression of residuals versus fitted model values and Q–Q plots of expected ver-
sus observed residual values were computed in order to validate the model. 
The initial model included the age of the participants (6–14 years), status of co-infec-
tion with STH, gender, and BMI values as fixed effects, because these parameters are var-
iables known to affect schistosome infection intensity and prevalence. The time point at 
which Kato–Katz samples were obtained and the school in which the child attends were 
also included in the model to assess the effect of blood type on S. mansoni intensity, clear-
ance, and variability between the schools. 
Model selection was performed by using the drop1 function in R, which compares 
all possible models that can be constructed by each time, removing the lowest estimate 
variable, which included the removal of BMI, gender, and Rh type, to obtain a parsimoni-
ous final model. ABO blood group was not a significant predictor, but because of its bio-
logical importance, it was retained during model selection. 
 
Figure 1. Kato–Katz thick smear sampling (three days of duplicate Kato–Katz at each time point) and
praziquantel treatment timeline, indicating the weeks sampling occurred in each school. Triangles in-
dicate praziquantel administration given, after stool samples were collected, on that week, and circles
denote treatment was only administered to children with Schistosoma mansoni detected infections.
Because the schools were not all sampled on the same dates, the number of weeks at
follow-up was controlled for in the analysis. Participants were excluded from the study if
weight and height information collected at baseline or blood-group data were missing. Loss
to follow-up was high; therefore, only 265 individuals were included in the final analysis.
To assess the role that blood type plays in predisposition to infection and to deter-
mine its effect on clearance, prevalence, and intensity, a generalised linear mixed-effects
model was performed, using the glmmTMB [40] package in R ver. 3.5.1 [41]. Negative
binomial model assumptions were assessed by using several error structures, including
both nbinom1 and nbinom2 parameters, as well as Poisson distributions [40]. The nbinom2
error distribution had minimal residual variance compared with the other error structures
assessed and was therefore chosen as the best fit for the data. Residuals were assessed for
uniformity, using the DHARMa package [42]. Briefly, a bootstrapped simulation of residu-
als was performed, along with Kolmogorov–Smirnov uniformity tests; quantile regression
of residuals versus fitted model values and Q–Q plots of expected versus observed residual
values were computed in order to validate the model.
The initial model included the age of the participants (6–14 years), status of co-infection
with STH, gender, and BMI values as fixed effects, because these parameters are variables
known to affect schistosome infection intensity and prevalence. The time point at which
Kato–Katz samples were obtained and the school in which the child attends were also
included in the model to assess the effect of blood type on S. mansoni intensity, clearance,
and variability between the schools.
Model selection was performed by usi g the drop1 function in R, which compares
ll possible models that can be constructed by each time, removing the lowest estimate
variable, which included the re oval of BMI, gender, and Rh type, to obtain a parsimonious
fin l mod l. ABO blood group was not a significant predictor, but becau e of its biological
importanc , it was retained during model selection.
3. Results
In the Ugandan villages of Bugoto, Bwondha, and Musubi, which have experie ced
over 15 years of regular praziquantel administration (either annually or bi-annually),
S. ma soni infection was detected in 190 (72%) individuals (n = 265) across the schools, with
prevalences of 86% in Bugoto, 71% in Bwondha, and 57% in Musubi and mean infection
intensities of 164.6 EPG (95% CI: 113.9–215.3), 108.4 EPG (95% CI: 73.4–143.5), and 92.6 EPG
(95% CI: 53.6–131.7), respectiv ly, at baseline. The most commonly occurring blood group
was O, with 39% of in ividuals in Bug to, 49% in Bwondha, and 39% in Musubi. There was
no significant difference between proportion of blood groups observed between the schools
(p = 0.390). Type AB occurred significantly less often (p < 0.001) than all other groups, with
a prevalence of 6%, 3%, and 1% in Bugoto, Bwondha, and Musubi, respectively. Only 4.8%
of individuals from all three schools had an Rh- blood group, and no individuals were
Rh- in Musubi. There was no significant association between blood groups and S. mansoni
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prevalence (p = 0.811). However, significant variation in prevalence occurred between the
schools at each time point (p < 0.001) (Figure 2).
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The incidence of Rh- individuals was low, at 4.8%, but slightly higher than other
studies conducted in similar regions [43,44]. However, because of its low estimate value,
Rh was removed from the final model.
Body mass index (BMI) was calculated based on the World Health Organization’s
(WHO) growth standards [45]; however, the best-fit model did not include this parameter,
due to the low estimate of this variable.
At baseline, 27 (10%) individuals across all three schools had a STH coinfection, while
only three (1%) were mono-infected with STHs. There was no significant relationship
between blood group and mono or coinfection with STHs (p = 0.101).
4. Discussion
The Ugandan Ministry of Health has been conducting community-wide MDAs to
control schistosomiasis in the Mayuge district since 2004. As with many areas in sub-
Saharan Africa, despite these efforts, the burden remains high. This may be partly explained
by low MDA coverage [46], but even when children are given observed praziquantel
treatment, clearance rates are low [47], many are very rapidly reinfected [2,47], and several
remain heavily infected over repeated time points. This could indicate a behavioural or
a biological predisposition to rapid and heavy reinfections. This investigation, part of a
larger host-factor study, focused on blood group as a potential biological factor which may
be driving the high S. mansoni prevalence, intensities, low clearance, and rapid reinfections
seen in this area of Uganda. However, no association was found between host blood-group
type and S. mansoni infection prevalence or intensity at baseline or over time with two
praziquantel treatments, and there was no association with clearance rates, egg reduction
rates or co-infection with STHs.
The examination of the impact of blood type on disease incidence is important to help
further our understanding of host factors driving the persistence of infection transmission.
Research looking specifically at S. mansoni has produced contradictory results regarding
the influence that blood type has on schistosomiasis. The results of this study showed no
correlation between blood type and S. mansoni infection dynamics: prevalence, intensity,
clearance, or reinfection rates. In the majority of other publications, as outlined above,
schistosomiasis infection status was also determined using the Kato–Katz method; however,
most of the other Kato–Katz/blood-type studies only obtained one stool sample at one time
point. A more robust depiction of the infection status of the cohort is provided by using
duplicate Kato–Katz slides over three days and repeating at follow-up time points [48,49],
as was conducted in this study. Obtaining only one slide per time point increases the risk
of false negatives [50]. Berhe et al. noted that false negatives occurred when using either
a single Kato–Katz reading or three slides at a rate of 68% and 21%, respectively [51]. To
mitigate limitations of the Kato–Katz method, the participants in this study provided stool
samples at three time points, for a total of 18 (six per time point) Kato–Katz slides, thus
enabling a better depiction of infection status and changes exhibited over time. Expanding
on previous studies by assessing the effect of blood group longitudinally, this fully powered
study indicates that it does not play a role in the risk of reinfection and clearance rates
in these highly endemic villages in Uganda. It may be that the force of infection is so
high in these villages that individuals become infected despite the presence or absence of
blood-group antigens. However, there was also no association between blood group and
infection intensities over time, which is a more sensitive measure for a predisposition to
infections in such high force of infection foci and would be expected to demonstrate an
effect if it existed here.
The incidence of Rh- individuals at 4.8% is slightly higher than other studies conducted
in similar regions [43,44]. However, its role in S. mansoni infection dynamics could not be
determined in this study, due to the disproportionate number of individuals with Rh- blood.
The association between age and infection prevalence and intensity suggests that the
risk of infection decreases with age. A relationship between age and infection intensity
has been described in numerous studies examining schistosomiasis and is an important
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risk factor for infection [52–55]. The driving factor behind this occurrence is thought to
be due to repeated exposure to S. mansoni causing an increased immunity toward the
pathogen [53,56]. It has also been suggested that an increase in age relates to changes in
water contact behaviour, thereby reducing the opportunity for reinfection [55,57]. The
association with age would suggest that continued work investigating age-related im-
munity may be imperative to advancing current knowledge to improve treatment and
prevention measures.
The relationship between the school an individual attended and S. mansoni infection
dynamics had a significant impact on infection profile. Several factors may be driving
this intra-divergence in infection dynamics, including variances in MDA history, MDA
coverage, water-contact behaviour, accessibility to sanitation and/or safe water, parasite
or host genetics, and host immunity. While blood group is not associated with S. mansoni
infection dynamics in this hyper-endemic region, further work is required to assess the
influence of other within-host factors that may play a role in the risk of S. mansoni infection,
in order to develop more targeted control programmes.
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